WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 201955

CAS#: 827031-83-4

Description: Thymectacin, also known as NB-1011, is a small molecule phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine with potential antineoplastic activity. Selectively active against tumor cells expressing high levels of thymidylate synthase (TS), BVdU pronucleotide analogue NB1011 is converted intracellularly by TS to bromovinyldeoxyuridine monophosphate (BVdUMP) which competes with the natural substrate, deoxyuridine monophosphate, for binding to TS. Unlike TS inhibitors, this agent is a reversible substrate for TS catalysis.

Chemical Structure

CAS# 827031-83-4

Theoretical Analysis

MedKoo Cat#: 201955
Name: Thymectacin
CAS#: 827031-83-4
Chemical Formula: C21H25BrN3O9P
Exact Mass: 573.05118
Molecular Weight: 574.3
Elemental Analysis: C, 43.92; H, 4.39; Br, 13.91; N, 7.32; O, 25.07; P, 5.39

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-02-25. Prices are subject to change without notice.

Thymectacin, purity > 98%, is available through custom synthesis . Minimum 1 gram order is requested. Current shipping out time is about 70 days after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: $30.00 (USA); from $45.00 (Canada); from $70.00 (international).

Synonym: NB1011; NB-1011; NB 1011; NB101; Thymectacin.

IUPAC/Chemical Name: (2S)-methyl 2-(((((2R,3S,5R)-5-(5-((E)-2-bromovinyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate


InChi Code: InChI=1S/C21H25BrN3O9P/c1-13(20(28)31-2)24-35(30,34-15-6-4-3-5-7-15)32-12-17-16(26)10-18(33-17)25-11-14(8-9-22)19(27)23-21(25)29/h3-9,11,13,16-18,26H,10,12H2,1-2H3,(H,24,30)(H,23,27,29)/b9-8+/t13-,16-,17+,18+,35?/m0/s1

SMILES Code: C[C@H](NP(OC1=CC=CC=C1)(OC[C@H]2O[C@@H](N(C(N3)=O)C=C(/C=C/Br)C3=O)C[C@@H]2O)=O)C(OC)=O

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 574.3 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1. Congiatu, C.; McGuigan, C.; Jiang, W. G.; Davies, G.; Mason, M. D. Naphthyl phosphoramidate derivatives of BVdU as potential anticancer agents: Design, synthesis and biological evaluation. Nucleosides, Nucleotides & Nucleic Acids (2005), 24(5-7), 485-489. CODEN: NNNAFY ISSN:1525-7770. CAN 145:271969 AN 2005:1151332

2. Nakata, Rieko. Development of novel anticancer agent targeting thymidylate synthase. Kagaku to Kogyo (Tokyo, Japan) (2003), 56(11), 1260. CODEN: KAKTAF ISSN:0022-7684. CAN 140:35079 AN 2003:927328

3. Dellinger, Ryan W.; Karjian, Patricia L.; Neuteboom, Saskia T. C. NB1011 induces Ser15 phosphorylation of p53 and activates the G2/M checkpoint. Anti-Cancer Drugs (2003), 14(6), 449-455. CODEN: ANTDEV ISSN:0959-4973. CAN 140:35438 AN 2003:543256

4. Natarajan, Gita; John, Elizabeth; Maniar, Manoj. Formulation development of a nucleotide phosphoramidate. Pharmaceutical Technology (2003), 27(6), 66,68,70. CODEN: PTHEC9 ISSN:1543-2521. CAN 140:64854 AN 2003:515896

5. Sergeeva, Maria V.; Cathers, Brian E. Cellular transformation of the investigational new anticancer drug NB1011, a phosphoramidate of 5-(2-bromovinyl)-2'-deoxyuridine, results in modification of cellular proteins not DNA. Biochemical Pharmacology (2003), 65(5), 823-831. CODEN: BCPCA6 ISSN:0006-2952. CAN 139:190589 AN 2003:164629

6. Boyer, Christopher R.; Karjian, Paticia L.; Wahl, Geoffrey M.; Pegram, Mark; Neuteboom, Saskia T. C. Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011. [Erratum to document cited in CA138:248065]. Anti-Cancer Drugs (2002), 13(10), 1077. CODEN: ANTDEV ISSN:0959-4973. CAN 139:316719 AN 2003:54370

7. Boyer, Christopher R.; Karjian, Patricia L.; Wahl, Geoffrey M.; Pegram, Mark; Neuteboom, Saskia T. C. Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011. Anti-Cancer Drugs (2002), 13(1), 29-36. CODEN: ANTDEV ISSN:0959-4973. CAN 138:248065 AN 2002:694508

8. Neuteboom, Saskia T. C.; Karjian, Patricia L.; Boyer, Christopher R.; Beryt, Malgorzhata; Pegram, Mark; Wahl, Geoffrey M.; Shepard, H. Michael. Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, Bax, and GADD45 induction. Molecular Cancer Therapeutics (2002), 1(6), 377-384. CODEN: MCTOCF ISSN:1535-7163. CAN 137:272912 AN 2002:328912

9. Li, Qing; Boyer, Christopher; Lee, Jean Y.; Shepard, H. Michael. A novel approach to thymidylate synthase as a target for cancer chemotherapy. Molecular Pharmacology (2001), 59(3), 446-452. CODEN: MOPMA3 ISSN:0026-895X. CAN 134:361084 AN 2001:167005

10. Lackey, D. B.; Groziak, M. P.; Sergeeva, M.; Beryt, M.; Boyer, C.; Stroud, R. M.; Sayre, P.; Park, J. W.; Johnston, P.; Slamon, D.; Shepard, H. M.; Pegram, M. Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochemical Pharmacology (2001), 61(2), 179-189. CODEN: BCPCA6 ISSN:0006-2952. CAN 134:290064 AN 2001:24117

11. Sergeeva Oksana A; Khambatta H Godrej; Cathers Brian E; Sergeeva Maria V Kinetic properties of human thymidylate synthase, an anticancer drug target. Biochemical and biophysical research communications (2003), 307(2), 297-300. Journal code: 0372516. ISSN:0006-291X. PubMed ID 12859954 AN 2003330291


10mg / Not available

Additional Information